talazoparib,enzalutamide
pfizer,astellas
['prostate', 'crpc', 'lba17', 'talapro-2']
some exciting oral abstracts today at #ascogu23, including in session a: prostate cancer. an update from the phase 3 talapro-2 trial presented by (tala) + enza vs placebo &amp; enza as first-line treatment in patients with mcrpc. abstract:lba17 16:10 gmt/10:10 cst
#meded
COR2ED bringing you Independent Medical Education developed 
by GU CONNECT, international experts in GenitoUrinary (GU) oncology